Study analysis · The Journal of arthroplasty · 2024
Diabetes drugs like Ozempic may increase joint damage risk in diabetics — but not in non-diabetics, new study finds.
People with diabetes who take GLP-1 drugs like Ozempic are more likely to get worse hip and knee arthritis over five years.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched a lot of people over five years to see if those who took GLP-1 drugs were more likely to get knee or hip arthritis. It found a link, but it can't prove the medicine caused the arthritis because it didn’t randomly assign people to take it.
What’s the bottom line?
This study looked at whether people with diabetes who take GLP-1 drugs are more likely to get joint problems in their hips or knees over five years.
How strong is this study?
The study looked at a huge number of patients and tried to compare similar people using special math tricks. But because it didn’t randomly assign who took the drug, there might be other hidden reasons why one group had more arthritis. So, we have to be careful not to jump to conclusions.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=1094198)+20/20
- Follow-up+10/10
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study using propensity score matching. While it controls for several confounders, it cannot account for all unmeasured or unknown confounders. Randomization is not mentioned, so causation cannot be inferred.
Key takeaways
- 01
Diabetic patients on GLP-1 drugs had 52% to 78% higher risk of hip or knee arthritis.
- 02
They also got more joint injections.
- 03
Obese people without diabetes on these drugs did not have higher joint risks.
- 04
The results suggest GLP-1 drugs may be linked to worse joint issues in diabetics, but not in people without diabetes, which could matter when choosing treatments.
Surprising findings
- GLP-1-RAs were linked to *worse* joint outcomes in diabetics, despite prior research suggesting they might protect joints.Earlier studies proposed that GLP-1 drugs could reduce inflammation and even reverse joint damage. This large observational study found the opposite in diabetic patients — a 50–78% higher risk of OA progression.
Practical takeaways
If you have diabetes and are starting a GLP-1 drug, discuss joint health monitoring with your doctor, especially if you have existing joint pain.
The study only shows association, not causation, and residual confounding (e.g., activity levels, weight loss speed) may influence results. Full methodology not available.
low confidenceFor non-diabetic individuals using GLP-1 drugs for weight loss, this study suggests no increased risk of hip or knee arthritis over five years.
Findings limited to five-year outcomes; long-term effects unknown. Study did not assess other joint issues or mechanisms.
low confidenceWhy this study matters
GLP-1 Drugs Linked to Higher Arthritis Risk in Diabetics
In both obese and non-obese diabetic patients, GLP-1-RA use was associated with a 52% to 78% higher risk of developing hip or knee osteoarthritis over five years. For example, obese diabetics on GLP-1-RAs had a 63% higher risk of hip OA (HR: 1.63) and 52% higher risk of knee OA (HR: 1.52).
Millions of people with diabetes are using these popular drugs for weight and blood sugar control — but this suggests they might be harming their joints at the same time.
More Joint Injections, But Same Surgery Rates
Diabetic patients on GLP-1-RAs received more major joint injections — like steroid shots — over five years, indicating worse joint pain or inflammation. However, there was no difference in total hip or knee replacement rates between users and non-users.
This suggests the drugs may worsen joint symptoms or early degeneration without leading to more severe end-stage disease requiring surgery.
No Joint Risk in Non-Diabetics on GLP-1 Drugs
Among obese people without diabetes, GLP-1-RA use showed no increased risk of hip or knee OA, joint injections, or surgeries over five years. This contrast highlights that the joint risk may depend on having diabetes, not just the drug.
If you're using Ozempic for weight loss but don’t have diabetes, your joints may not be at higher risk — a crucial distinction for the growing number of off-label users.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether people with diabetes who take GLP-1 drugs are more likely to get joint problems in their hips or knees over five years.
Research results
Diabetic patients on GLP-1 drugs had 52% to 78% higher risk of hip or knee arthritis. They also got more joint injections. Obese people without diabetes on these drugs did not have higher joint risks.
What this means - more context
The results suggest GLP-1 drugs may be linked to worse joint issues in diabetics, but not in people without diabetes, which could matter when choosing treatments.
The study aimed to investigate the association between glucagon-like peptide-1 receptor agonist (GLP-1-RA) use and the progression to hip and knee osteoarthritis (OA), major joint injections, and total joint arthroplasty over a five-year period in obese diabetic, non-obese diabetic, and obese non-diabetic patients.
In obese and non-obese diabetic patients, GLP-1-RA use was associated with a higher risk of progression to hip and knee OA and increased rates of major joint injections over five years compared to matched controls not using GLP-1-RAs. No such associations were found in obese non-diabetic patients. There was no difference in total hip or knee arthroplasty rates between GLP-1-RA users and non-users in diabetic cohorts.
Methods Used
The study used a collaborative network analytics platform to analyze data from obese diabetic (n = 1,094,198), obese non-diabetic (n = 916,235), and non-obese diabetic (n = 157,305) patients with an index visit between 2015 and 2017. Patients with pre-existing hip or knee OA were excluded. Propensity score matching (1:1) was used to balance cohorts on age, sex, race, BMI, and HbA1c. Cox proportional hazards models were used to assess hazard ratios for primary outcomes over five years.
Main Finding
GLP-1-RA use was associated with increased risk of progression to hip OA (HR: 1.63, 95% CI: 1.46–1.82) and knee OA (HR: 1.52, 95% CI: 1.41–1.64) in obese diabetic patients, and hip OA (HR: 1.78, 95% CI: 1.50–2.10) and knee OA (HR: 1.58, 95% CI: 1.39–1.80) in non-obese diabetic patients. No differences were observed in obese non-diabetic patients. GLP-1-RA users in diabetic groups had higher rates of major joint injections but no difference in total joint arthroplasty rates.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Association does not imply causation - unmeasured confounding possible
- •Propensity score matching used, but residual confounding may remain
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
GLP-1-RAs were linked to *worse* joint outcomes in diabetics, despite prior research suggesting they might protect joints.
Earlier studies proposed that GLP-1 drugs could reduce inflammation and even reverse joint damage. This large observational study found the opposite in diabetic patients — a 50–78% higher risk of OA progression.
Practical Takeaways
If you have diabetes and are starting a GLP-1 drug, discuss joint health monitoring with your doctor, especially if you have existing joint pain.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched a lot of people over five years to see if those who took GLP-1 drugs were more likely to get knee or hip arthritis. It found a link, but it can't prove the medicine caused the arthritis because it didn’t randomly assign people to take it.
Strengths
- Large sample size (over 1 million patients)
- Five-year follow-up period for all patients
- Use of 1:1 propensity score matching to balance key covariates (age, sex, race, BMI, HbA1c)
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status: Unknown → cannot be classified as RCT
- Blinding status: Unknown → likely unblinded observational design
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at whether people with diabetes who take GLP-1 drugs are more likely to get joint problems in their hips or knees over five years.
Research results
Diabetic patients on GLP-1 drugs had 52% to 78% higher risk of hip or knee arthritis. They also got more joint injections. Obese people without diabetes on these drugs did not have higher joint risks.
What this means - more context
The results suggest GLP-1 drugs may be linked to worse joint issues in diabetics, but not in people without diabetes, which could matter when choosing treatments.
The study aimed to investigate the association between glucagon-like peptide-1 receptor agonist (GLP-1-RA) use and the progression to hip and knee osteoarthritis (OA), major joint injections, and total joint arthroplasty over a five-year period in obese diabetic, non-obese diabetic, and obese non-diabetic patients.
In obese and non-obese diabetic patients, GLP-1-RA use was associated with a higher risk of progression to hip and knee OA and increased rates of major joint injections over five years compared to matched controls not using GLP-1-RAs. No such associations were found in obese non-diabetic patients. There was no difference in total hip or knee arthroplasty rates between GLP-1-RA users and non-users in diabetic cohorts.
Methods Used
The study used a collaborative network analytics platform to analyze data from obese diabetic (n = 1,094,198), obese non-diabetic (n = 916,235), and non-obese diabetic (n = 157,305) patients with an index visit between 2015 and 2017. Patients with pre-existing hip or knee OA were excluded. Propensity score matching (1:1) was used to balance cohorts on age, sex, race, BMI, and HbA1c. Cox proportional hazards models were used to assess hazard ratios for primary outcomes over five years.
Main Finding
GLP-1-RA use was associated with increased risk of progression to hip OA (HR: 1.63, 95% CI: 1.46–1.82) and knee OA (HR: 1.52, 95% CI: 1.41–1.64) in obese diabetic patients, and hip OA (HR: 1.78, 95% CI: 1.50–2.10) and knee OA (HR: 1.58, 95% CI: 1.39–1.80) in non-obese diabetic patients. No differences were observed in obese non-diabetic patients. GLP-1-RA users in diabetic groups had higher rates of major joint injections but no difference in total joint arthroplasty rates.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Association does not imply causation - unmeasured confounding possible
- •Propensity score matching used, but residual confounding may remain
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
GLP-1-RAs were linked to *worse* joint outcomes in diabetics, despite prior research suggesting they might protect joints.
Earlier studies proposed that GLP-1 drugs could reduce inflammation and even reverse joint damage. This large observational study found the opposite in diabetic patients — a 50–78% higher risk of OA progression.
Practical Takeaways
If you have diabetes and are starting a GLP-1 drug, discuss joint health monitoring with your doctor, especially if you have existing joint pain.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched a lot of people over five years to see if those who took GLP-1 drugs were more likely to get knee or hip arthritis. It found a link, but it can't prove the medicine caused the arthritis because it didn’t randomly assign people to take it.
Strengths
- Large sample size (over 1 million patients)
- Five-year follow-up period for all patients
- Use of 1:1 propensity score matching to balance key covariates (age, sex, race, BMI, HbA1c)
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status: Unknown → cannot be classified as RCT
- Blinding status: Unknown → likely unblinded observational design
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study looked at a huge number of patients and tried to compare similar people using special math tricks. But because it didn’t randomly assign who took the drug, there might be other hidden reasons why one group had more arthritis. So, we have to be careful not to jump to conclusions.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=1094198)+20/20
- Follow-up+10/10
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 553 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study using propensity score matching. While it controls for several confounders, it cannot account for all unmeasured or unknown confounders. Randomization is not mentioned, so causation cannot be inferred.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Contradicted
Evidence contradicts this claim.
Evidence